Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation

 Supported by the National Psoriasis Foundation.

 Disclosure: Dr Van Voorhees has received grant support from Amgen, Astellas, and Warner Chilcott. She has been a consultant, advisory board member, or speaker for Amgen, Centocor, Connetics, Genentech, and Warner Chilcott and a drug safety monitoring board member for Synta. She is a major stockholder in Merck. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech. She has been a clinical investigator for Amgen and Centocor. Dr Korman has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott. He has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Ms Young has served on the advisory board or been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Bebo is employed by the National Psoriasis Foundation. The foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Dr Rosenbach has no conflicts of interest to declare.

 Consensus: The medical board of the National Psoriasis Foundation reviewed and endorsed this manuscript by a majority vote.

PII: S0190-9622(09)00690-2

doi:10.1016/j.jaad.2009.05.048

© 2009 American Academy of Dermatology, Inc. Published by Elsevier Inc All rights reserved.